Skip to main content
OpenTrials
Completed

NCT Number: NCT06763887

Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population

The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Air Force Military Medical University

Xi'an, Shaanxi, 710004, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • He was infected with COVID-19 from November to December 2022;
  • Have not been infected with COVID-19 (the subject said that he was not infected and signed the informed consent form);
  • Those who agree and sign the informed consent form.

Exclusion criteria

  • Missing or incomplete questionnaires that affect research results;
  • Individuals with combined dysfunction of important organs such as the heart, liver, and lungs;
  • Mental and behavioral abnormalities;
  • Intellectual disability;
  • Under 18 years old or over 75 years old;
  • Low understanding and communication skills.

Treatment and study plan

No interventions

Other

No intervention

Primary outcomes

  1. PBMC

    Time frame: About two and a half years

    When conducting blood sample analysis, we focus on separating and evaluating in detail the composition and counting of peripheral blood mononuclear cell (PBMC). This process involves identifying and quantifying various types of mononuclear cells in the sample, such as lymphocytes, monocytes, etc. These cells are crucial for understanding an individual's immune status. Through precise separation techniques and advanced cell analysis methods, we are able to obtain accurate and detailed reports on the classification and quantity of mononuclear cells.

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jan 8, 2025
Registry last updated
Jan 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.